Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator

Dorzagliatin is a novel allosteric glucokinase activator targeting both pancreatic and hepatic glucokinase currently under clinical investigation for treatment of type 2 diabetes (T2D). This study aimed to investigate the effect of renal impairment (RI) on dorzagliatin’s pharmacokinetics (PKs) and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Jia, Fu, Ping, Ren, Shuang, Hu, Chao, Wang, Ying, Jiao, Chengfeng, Li, Ping, zhao, Yu, Tang, Cui, Qian, Yuli, Yang, Rong, Dong, Yanli, Rong, Jing, Wang, Yaohui, Jin, Xiaowei, Sun, Yu, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841463/
https://www.ncbi.nlm.nih.gov/pubmed/34706161
http://dx.doi.org/10.1111/cts.13174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841463/
https://www.ncbi.nlm.nih.gov/pubmed/34706161
http://dx.doi.org/10.1111/cts.13174

Ejemplares similares